The role of inflammation in diabetic cardiomyopathy

References

• George B, Cebioglu M, Yeghiazaryan K. Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J. 2010;1(1):13–18.
   Google Scholar
• Copeland KC, Becker D, Gottschalk M, Hale D. Type 2 diabetes in children and adolescents: risk factors, diagnosis, and treatment. Clinical Diabetes. 2005;23(4):181–185.
   Google Scholar
• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(27):1047–1053.
   Google Scholar
• International Diabetes Federation (IDF). IDF Diabetes Atlas. 4th ed. Brussels: IDF; 2010.
   Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26(2):77–82.
   Google Scholar
• Tuomilehto J, Lindström J. The major diabetes prevention trials. Curr Diab Rep. 2003;3(2):115–122.
   Google Scholar
• Fisher M. Diabetes: can we stop the time bomb? Heart. 2003;89 Suppl 2: ii28-ii30; discussion ii35-ii37.
   Web of Science ®Google Scholar
• Bäcklund T, Palojoki E, Saraste A, et al. Sustained cardiomyocyte apoptosis and left ventricular remodelling after myocardial infarction in experimental diabetes. Diabetologia. 2004;47(2):325–330.
   Web of Science ®Google Scholar
• Yang ZH, Peng XD. Insulin resistance and heart injury in rats with insulin resistance or type 2 diabetes mellitus. Acta Cardiol. 2010;65(3):329–335.
   Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34.
   PubMed Web of Science ®Google Scholar
• Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol. 1996;77(11):1017–1020.
   PubMed Web of Science ®Google Scholar
• Rubler S, Dlugash J,Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602.
   PubMed Web of Science ®Google Scholar
• Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68(1):85–89.
   PubMed Web of Science ®Google Scholar
• Shrestha NR, Sharma SK, Karki P, Shrestha NK, Acharya P. Echocardiographic evaluation of diastolic function in asymptomatic type 2 diabetes. J Nepal Med Assoc. 2009;48(173):20–23.
   Google Scholar
• Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543–567.
   PubMed Web of Science ®Google Scholar
• Tziakas DN, Chalikias GK, Kaski JC. Epidemiology of the diabetic heart. Coron Artery Dis. 2005;16 Suppl 1:S3–S10.
   Google Scholar
• Fang ZY, Yuda S, Anderson V, Short L, Case C, Marwick TH. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003;41(4):611–617.
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Karvounis HI, Dalamanga EG, et al. Early diastolic impairment of diabetic heart: the significance of right ventricle. Int J Cardiol. 2007;114(2):218–223.
   Web of Science ®Google Scholar
• Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE. Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology. 2002;98(1–2):33–39.
   PubMed Web of Science ®Google Scholar
• Hamblin M, Friedman DB, Hill S, Caprioli RM, Smith HM, Hill MF Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol. 2007;42(4):884–895.
   Web of Science ®Google Scholar
• Loganathan R, Bilgen M, Al-Hafez B, Alenezy MD, Smirnova IV. Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging. Cardiovasc Diabetol. 2006;5:7.
   Web of Science ®Google Scholar
• Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol. 2002;283(3):H976–H982.
   Web of Science ®Google Scholar
• Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M. LV function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 1992;70(3):371–378.
   Web of Science ®Google Scholar
• Boyer JK, Thanigaraj S, Schechtman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93(7):870–875.
   PubMed Web of Science ®Google Scholar
• Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol. 1995;76(16):1173–1176.
   Web of Science ®Google Scholar
• Andersen NH, Poulsen SH, Helleberg K, Ivarsen P, Knudsen ST, Mogensen CE. Impact of essential hypertension and diabetes mellitus on left ventricular systolic and diastolic performance. Eur J Echocardiogr. 2003;4(4):306–312.
   Google Scholar
• Ballo P Cameli M, Mondillo S, et al. Impact of diabetes and hypertension on left ventricular longitudinal systolic function. Diabetes Res Clin Pract. 2010;90(2):209–215.
   Web of Science ®Google Scholar
• Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci. 2001;69(5):527–542.
   Web of Science ®Google Scholar
• Mytas DZ, Stougiannos PN, Zairis MN, Foussas SG, Pyrgakis VN, Kyriazis IA. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options. J Diabetes Complications. 2009;23(4):273–282.
   Web of Science ®Google Scholar
• Radovits T, Korkmaz S, Loganathan S, et al. Comparative investigation of the left ventricular pressure-volume relationship in rat models of type 1 and type 2 diabetes mellitus. Am J Physiol Heart Circ Physiol. 2009;297(1):H125–H133.
   Web of Science ®Google Scholar
• Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010;16(12):971–979.
   PubMed Web of Science ®Google Scholar
• Dorn GW 2nd. The fuzzy logic of physiological cardiac hypertrophy. Hypertension. 2007;49(5):962–970.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Roman MJ, Parancias M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation. 2000;101(19):2271–2276.
   PubMed Web of Science ®Google Scholar
• Karason K, Sjôstrôm L, Wallentin I, Peltonen M. Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. Eur Heart J. 2003;24(16):1500–1505.
   Web of Science ®Google Scholar
• Holmâng A, Yoshida N, Jennische E, Waldenstrôm A, Bj ôrntorp P The effects of hyperinsulinaemia on myocardial mass, blood pressure regulation and central haemodynamics in rats. Eur J Clin Invest. 1996;26(11):973–978.
   Web of Science ®Google Scholar
• Barouch LA, Berkowitz DE, Harrison RW, O’Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003;108(6):754–759.
   Web of Science ®Google Scholar
• van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117(1):43–51.
   PubMed Web of Science ®Google Scholar
• Mizushige K, Yao L, Noma T, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101(8):899–907.
   PubMed Web of Science ®Google Scholar
• Tschôpe C, Walther T, Kôniger J, et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J. 2004;18(7):828–835.
   Web of Science ®Google Scholar
• Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582–592.
   PubMed Web of Science ®Google Scholar
• Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003;21(1):3–12.
   PubMed Web of Science ®Google Scholar
• Brüning JC, Winnay J, Cheatham B, Kahn CR. Differential signaling by insulin receptor substrate 1 (IRS-1) and IRS-2 in IRS-1-deficient cells. Mol Cell Biol. 1997;17(3):1513–1521.
   PubMed Web of Science ®Google Scholar
• Zecchin HG, Carvalheira JB, Saad MJ. Mecanismos moleculares de resistência à insulina na síndrome metabólica [Molecular mechanisms of insulin resistance in metabolic syndrome]. Rev Soc Cardiol Estado de Sâo Paulo. 2004;14(4):574–589. Portuguese.
   Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007;28(5):463–491.
   Web of Science ®Google Scholar
• Perseghin J, Petersen K, Shulman G. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003;27 Suppl 3:S6–S11.
   Google Scholar
• Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem. 1998;180(1–2):53–57.
   PubMed Web of Science ®Google Scholar
• Poitout V, Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes – a convergence of glucotoxicity and lipotoxicity. Endocrinology. 2002;143(2):339–342.
   PubMed Web of Science ®Google Scholar
• Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: a key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol. 2010;88(3):233–240.
   PubMed Web of Science ®Google Scholar
• Eckel J, Reinauer H. Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations. Biochem Soc Trans. 1990;18(6):1125–1127.
   Web of Science ®Google Scholar
• Finck BN, Han X, Courtois M, et al. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci U S A. 2003;100(3):1226–1231.
   PubMed Web of Science ®Google Scholar
• Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117(10):2791–2801.
   Web of Science ®Google Scholar
• Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87(3):179–183.
   PubMed Web of Science ®Google Scholar
• Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785–792.
   PubMed Web of Science ®Google Scholar
• Yamagishi S, Matsui T, Nakamura K. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes. Curr Drug Targets. 2007;8(10):1138–1143.
   PubMed Web of Science ®Google Scholar
• Yan SF, D’Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med. 2007;7(8):699–710.
   PubMed Web of Science ®Google Scholar
• Bidasee KR, Nallani K, Yu Y, et al. Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels. Diabetes. 2003;52(7):1825–1836.
   Web of Science ®Google Scholar
• Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47(6):859–866.
   PubMed Web of Science ®Google Scholar
• Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res. 2007;55(6):498–510.
   PubMed Web of Science ®Google Scholar
• Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappa B/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol. 2009;8:8.
   PubMed Web of Science ®Google Scholar
• Yu Q, Gao F, Ma XL. Insulin says NO to cardiovascular disease. Cardiovasc Res. 2011;89(3):516–524.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation. 2002;105(14):1656–1662.
   PubMed Web of Science ®Google Scholar
• Niklason A, Hedner T, Niskanen L, Lanke J; Captopril Prevention Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients – a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004;22(3):645–652.
   Web of Science ®Google Scholar
• de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav. 2010;100(5):525–534.
   Web of Science ®Google Scholar
• Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46(5):821–826.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Takai S, Yamashita C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Curr Vasc Pharmacol. 2010;8(2):189–197.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Winterfield JR, Rytlewski JA, Ferrannini E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res. 2008;5(1):59–66.
   PubMed Web of Science ®Google Scholar
• Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension. 2003;42(2):206–212.
   PubMed Web of Science ®Google Scholar
• Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264(3):224–236.
   PubMed Web of Science ®Google Scholar
• Richey JM, Ader M, Moore D, Bergman RN. Angiotensin II induces insulin resistance independent of changes in interstitial insulin. Am J Physiol. 1999;277(5 Pt 1):E920–E926.
   Google Scholar
• Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57(12):3297–3306.
   PubMed Web of Science ®Google Scholar
• Lee JH, Xia S, Ragolia L. Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiol Regul Integr Comp Physiol. 2008;295(1):R144–R154.
   Web of Science ®Google Scholar
• Siddiqui AH, Hussain T. Enhanced AT 1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol. 2007;292(4):H1722–H1727.
   Web of Science ®Google Scholar
• Fiordaliso F, Li B, Latini R, et al. Mycocyte death in streptozotocin-induced diabetes in rats is angiotensin II-dependent. Lab Invest. 2000;80(4):513–527.
   PubMed Web of Science ®Google Scholar
• Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl. 1997;15(6):S13–S19.
   Google Scholar
• Dostal DE, Booz GW, Baker KM. Regulation of angiotensinogen gene expression and protein in neonatal rat cardiac fibroblasts by glucocorticoid and beta-adrenergic stimulation. Basic Res Cardiol. 2000;95(6):485–490.
   Web of Science ®Google Scholar
• Lorenzo O, Picatoste B, Ares-Carrasco S, Ramírez E, Egido J, Tuñón J. Potential role of nuclear factor kB in diabetic cardiomyopathy. Mediators Inflamm. 2011:652097.
   Web of Science ®Google Scholar
• Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud. 2004;1(4):165–174.
   PubMedGoogle Scholar
• Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;148(7):3356–3363.
   PubMed Web of Science ®Google Scholar
• Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148(1):241–251.
   PubMed Web of Science ®Google Scholar
• Donath MY, Sterling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl). 2003;81(8):455–470.
   PubMed Web of Science ®Google Scholar
• Yu XY, Chen HM, Liang JL, et al. Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS One. 2011;6(1):e16239.
   Web of Science ®Google Scholar
• Mano Y, Anzai T, Kaneko H, et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ J. 2011;75(7):1717–1727.
   PubMed Web of Science ®Google Scholar
• Westermann D, Rutschow S, Van Linthout S, et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia. 2006;49(10):2507–2513.
   Web of Science ®Google Scholar
• Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman ML, Mann DL. Tumor necrosis factor-a provokes a hypertrophic growth response in adult cardiac myocytes. Circulation. 1997;95(5):1247–1252.
   PubMed Web of Science ®Google Scholar
• Sun M, Dawood F, Wen WH, et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110(20):3221–3228.
   Web of Science ®Google Scholar
• Younce CW, Wang K, Kolattukudy PE. Hyperglycemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovas Res. 2010;87:665–674.
   PubMed Web of Science ®Google Scholar
• Ares-Carrasco S, Picatoste B, Benito-Martín A, et al. Myocardial fibrosis and apoptosis, but not inflammation, are present in longterm experimental diabetes. Am J Physiol Heart Circ Physiol. 2009;297(6):H2109–H2119.
   Web of Science ®Google Scholar
• Ares-Carrasco S, Picatoste B, Camafeita E, et al. Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARa in the associated hypertrophy. J Proteomics. 2012;75(6):1816–1829.
   Web of Science ®Google Scholar
• Kawaguchi M, Techigawara M, Ishihata T, et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels. 1997;12(6):267–274.
   Web of Science ®Google Scholar
• Westermann D, Rutschow S, Jäger S, et al. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007;56(3):641–646.
   Web of Science ®Google Scholar
• Kaneko K, Kanda T, Yokoyama T, et al. Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol. 1997;97(1):3–12.
   Google Scholar
• Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res. 2000;87(12):1195–1201.
   PubMed Web of Science ®Google Scholar
• Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-K B activation, monocyte chemoattractant protein-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95(6):1532–1541.
   PubMed Web of Science ®Google Scholar
• Hopps E, Canino B, Caimi G. Effects of exercise on inflammation markers in type 2 diabetic subjects. Acta Diabetol. 2011;48(3):183–189.
   Web of Science ®Google Scholar
• de Lemos ET, Reis F, Baptista S, et al. Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type 2) diabetic rats. Med Sci Monit. 2007;13(8):BR168-BR174.
   Web of Science ®Google Scholar
• Teixeira de Lemos E, Reis F, Baptista S, et al. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition. 2009;25(3):330–339.
   PubMed Web of Science ®Google Scholar
• Teixeira-Lemos E, Nunes S, Teixeira F, Reis F. Regular physical exercise training assists in preventing type 2 diabetes development: focus on its antioxidant and anti-inflammatory properties. Cardiovasc Diabetol. 2011;10:12.
   PubMed Web of Science ®Google Scholar
• Teixeira de Lemos E, Pinto R, Oliveira J, et al. Differential effects of acute (extenuating) and chronic (training) exercise on inflammation and oxidative stress status in an animal model of type 2 diabetes mellitus. Mediators Inflamm. 2011;2011:253061.
   Web of Science ®Google Scholar
• Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002;105(7):804–809.
   PubMed Web of Science ®Google Scholar
• Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET. Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation. 2002;105(5):564–569.
   Web of Science ®Google Scholar
• Mao XM, Liu H, Tao XJ, Yin GP, Li Q, Wang SK. Independent antiinflammatory effect of insulin in newly diagnosed type 2 diabetes. Diabetes Metab Res Rev. 2009;25(5):435–441.
   Web of Science ®Google Scholar
• Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Insulin as an antiinflammatory and antiatherogenic modulator. J Am Coll Cardiol. 2009;53(Suppl 5):S14–S20.
   Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• Gundewar S, Calvert JW, Jha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circ Res. 2009;104(3):403–411.
   PubMed Web of Science ®Google Scholar
• Xie Z, Lau K, Eby B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60(6):1770–1778.
   PubMed Web of Science ®Google Scholar
• Caballero AE, Delgado A, Aguilar-Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebocontrolled randomized clinical trial. J Clin Endocrinol Metab. 2004;89(8):3943–3948.
   Web of Science ®Google Scholar
• Kim SK, Zhao ZS, Lee YJ, et al. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev. 2003;19(6):487–493.
   Web of Science ®Google Scholar
• Tsuji T, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol. 2001;38(6):868–874.
   Web of Science ®Google Scholar
• Bibra HV Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diabetes Vasc Dis Res. 2008;5(4):310–318.
   Web of Science ®Google Scholar
• Terui G, Goto T, Katsuta M, Aoki I, Ito H. Effect of pioglitazone on left ventricular diastolic function and fibrosis of type III collagen in type 2 diabetic patients. J Cardiol 2009;54(1):52–58.
   Web of Science ®Google Scholar
• Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104(14):1670–1675.
   Web of Science ®Google Scholar
• Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49(16):1696–1704.
   Web of Science ®Google Scholar
• Naka KK, Pappas K, Papathanassiou K, et al. Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study. Cardiovasc Diabetol. 2010;9:57.
   Web of Science ®Google Scholar
• Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond). 2004;107(6):539–557.
   PubMed Web of Science ®Google Scholar
• Takano H, Nagai T, Asakawa M, et al. Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res. 2000;87(7):596–602.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al; American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation. October 7, 2003;108(23):2941–2948.
   PubMed Web of Science ®Google Scholar
• Cheng AY, Fantus IG. Thiazolidinedione-induced congestive heart failure. Ann Pharmacother. 2004;38(5):817–820.
   Web of Science ®Google Scholar
• Finck BN, Kelly DP. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 2006;116(3):615–622.
   PubMed Web of Science ®Google Scholar
• Leroy C, Tricot S, Lacour B, Grynberg A. Protective effect of eicosapentaenoic acid on palmitate-induced apoptosis in neonatal cardiomyocytes. Biochim Biophys Acta. 2008;1781(11–12):685–693.
   Web of Science ®Google Scholar
• Bishopric NH, Andreka P, Slepak T, Webster KA. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr Opin Pharmacol. 2001;1(2):141–150.
   PubMedGoogle Scholar
• Lee SD, Kuo WW, Lin JA, et al. Effects of long-term intermittent hypoxia on mitochondrial and Fas death receptor dependent apoptotic pathways in rat hearts. Int J Cardiol. 2007;116(3):348–356.
   Web of Science ®Google Scholar
• Baraka A, AbdelGawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol Ther. 2010;15(2):175–181.
   Web of Science ®Google Scholar
• Pérez-Pérez R, Ortega-Delgado FJ, García-Santos E, et al. Differential proteomics of omental and subcutaneous adipose tissue reflects their unalike biochemical and metabolic properties. J Proteome Res. 2009;8(4):1682–1693.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab. 2011;13(4):302–312.
   PubMed Web of Science ®Google Scholar
• Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data. Cardiovasc Diabetol. 2011;11:6.
   Web of Science ®Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58(4):975–983.
   Web of Science ®Google Scholar
• Saraceni C, Broderick TL. Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D. 2007;8(3):45–53.
   Google Scholar
• Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94(2):316–323.
   PubMed Web of Science ®Google Scholar
• Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007;21(4):253–256.
   PubMed Web of Science ®Google Scholar
• Ossum A, van Deurs U, Engstrom T, Jensen JS, Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1 (9–36) a in an isolated rat heart. Pharmacol Res. 2009;60(5):411–417.
   Web of Science ®Google Scholar
• Hansotia T, Drucker DJ. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept. 2005;128(2):125–134.
   PubMedGoogle Scholar
• Yamagishi S, Matsui T. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr Pharm Des. 2011;17(38):4379–4385.
   PubMed Web of Science ®Google Scholar
• Verges B, Bonnard C, Renard E. Beyond glucose lowering: glucagonlike peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes Metab. 2011;37(6):477–488.
   PubMed Web of Science ®Google Scholar
• Hattori Y, Jojima T, Tomizawa A, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256–2263.
   PubMed Web of Science ®Google Scholar
• Mells JE, Fu PP, Sharma S, et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol. 2012;302(2): G225–G235.
   PubMed Web of Science ®Google Scholar
• Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14(1):14–21.
   PubMed Web of Science ®Google Scholar
• Chaykovska L, von Websky K, Rahnenführer J, et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One. 2011;6(11):e27861.
   PubMed Web of Science ®Google Scholar
• Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). MediatorsInflamm. 2010;2010:Article ID 592760.
   Google Scholar
• Mega C, Teixeira de Lemos E, Vala H, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res. 2011;2011: Article ID 162092.
   Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361(9374):2005–2016.
   PubMed Web of Science ®Google Scholar
• Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108(10):1429–1437.
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23 Suppl 1):III39-III43.
   Web of Science ®Google Scholar
• Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Antiinflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63(1):12–23.
   PubMed Web of Science ®Google Scholar
• Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47(2):332–337.
   Web of Science ®Google Scholar
• Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007;8(17):3061–3068.
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Riad A, Dhayat N, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia. 2007;50(9):1977–1986.
   PubMed Web of Science ®Google Scholar
• Ye P, Sheng L, Zhang C, Liu Y. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci. 2006;9(3):365–375.
   Web of Science ®Google Scholar
• Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–1538.
   PubMed Web of Science ®Google Scholar
• Zaman AK, Fujii S, Goto D, et al. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol. 2004;37(2):525–535.
   Web of Science ®Google Scholar
• Orea-Tej eda A, Colin-Ramirez E, Castillo-Martinez L, et al. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin. 2007;59(2):103–107.
   Google Scholar
• Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs. 2004;64(22):2537–2565.
   PubMed Web of Science ®Google Scholar
• Di Filippo C, Lampa E, Tufariello E, et al. Effects of irbesartan on the growth and differentiation of adipocytes in obese zucker rats. Obes Res. 2005;13(11):1909–1914.
   Google Scholar
• Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21(1):20–27.
   PubMed Web of Science ®Google Scholar
• Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103–1107.
   PubMed Web of Science ®Google Scholar
• Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoat-tractant protein-1. J Pharmacol Exp Ther 2003;305:846–853.
   Web of Science ®Google Scholar
• Nerry Serneri GG, Boddi M, Modesti PA, et al. Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component. Circ Res. 2004;94(12):1630–1637.
   Web of Science ®Google Scholar
• Gullestad L, Aukrust P, Ueland T, et al. Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol. 1999;34(7):2061–2067.
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35(3):714–721.
   PubMed Web of Science ®Google Scholar